Chemocentryx, Inc.

Schering Corporation

Leland Stanford Junior University

Amgen Inc.

Thomas J Schall

Zhenhua Miao

Daniel J Dairaghi

Rajinder Paul Singh

Albert Zlotnik

Zheng Wei

Maureen Howard

Israel Charo

Brian E McMaster

Brett Anthony Premack

Jennifer M Burns

Wei W Wang

James J Campbell

Gerard T Hardiman

Kevin B Bacon

Devora L Rossi

Penglie Zhang

J Fernando Bazan

Solomon Ungashe

Michael R Hanley

Andrew Pennell

Jennifa Gosling

J J Wright

Brett Permack

Kurt C Gish

John Jessen Wright

Dale John Talbot

Alain Vicari

Bretton Summers

Yibin Zeng

Shijie Li

Atsushi Miyajima

Takahiko Hara

Mark Penfold

Heiyoun Jung

Akihiko Yoshimura

Mark E T Penfold

Robert Berahovich

Julio Cesar Medina

Mark M Davis

Feng Xu

Anita Melikian

Alan M Krensky

Maureen C Howard

Karen Ebsworth

Xuemei Wang

Bazan Fernando J

Tassie Collins

Hossen Mahmud

Robert Berkovitz

Peter Staehr

Jan Jongstra

Christine Marie Janson

Brian E Mcmaster

John J Wright

A method of treating focal segmental glomerulosclerosis with a compound of Formula I is provided. FSGS may be primary (no known cause) or secondary. The secondary FSGS may be associated with infections or viruses such as HIV, diseases such as sickle cell disease or lupus, toxins or drugs such as anabolic steroids, heroin or pamidronate, nephron loss and hyperfiltration, such as with chronic pyelonephritis and reflux, morbid obesity, or diabetes mellitus.

Method of treating focal segmental glomerulosclerosis

Provided herein are compositions, methods and kits for treating inflammatory bowel disease (IBD) such as Crohn's disease and ulcerative colitis in a mammal in need thereof. The method include administering to a subject with IBD a combination therapy containing a therapeutically effective amount of a chemokine receptor 9 (CCR9) inhibitor compound and a therapeutically effective amount of an anti-IL-23 antibody. Also provided herein is a kit containing the CCR9 inhibitor compound and anti-IL-23 antibody.

Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-IL-23 blocking antibodies

Provided herein are methods for treating a subject suffering from a cutaneous neutrophilic inflammatory disease comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein each variable position is as defined herein. In some embodiments, the cutaneous neutrophilic inflammatory disease is Hidradenitis suppurativa (HS).

Methods of treating hidradenitis suppurativa

The present invention provides methods for reducing tumor burden, tumor growth, tumor progression, and/or metastasis in a subject suffering from a solid tumor cancer such as triple negative breast cancer. The methods include administering to a subject in need thereof a therapeutically effective amount of a PD-L1 inhibitor or a PD-1 inhibitor in combination with a small molecule chemokine receptor antagonist that blocks CCR1.

Reducing tumor burden by administering CCR1 antagonists in combination with PD-1 inhibitors or PD-L1 inhibitors

Provided herein are methods of treating focal segmental glomerulosclerosis, said methods include administering to a subject in need thereof a therapeutically effective amount of a CCR2 antagonist. In some embodiments, the CCR2 antagonist is used in monotherapy. In some embodiments, the CCR2 antagonist is used in combination therapy. In some embodiments, the additional therapeutic agent is a RAAS blocker and/or an endothelin receptor inhibitor. The CCR2 antagonist may have the structure of formula (I). 

Treatment of focal segmental glomerulosclerosis with CCR2 antagonists

Method of Treating Focal Segmental Glomerulosclerosis

The present disclosure is drawn to the combination therapy of a Chemokine Receptor 2 (CCR2) antagonist and a PD-1 and/or PD-L1 inhibitor in the treatment of cancer.

Combination therapy using a chemokine receptor 2 (CCR2) antagonist and a PD-1/PD-L1 inhibitor

Provided herein are compositions, methods and kits for treating inflammatory bowel disease (IBD) such as Crohn's disease and ulcerative colitis in a mammal in need thereof. The method include administering to a subject with IBD a combination therapy containing a therapeutically effective amount of a chemokine receptor 9 (CCR9) inhibitor compound and a therapeutically effective amount of an anti-&#x3b1;4&#x3b2;7 integrin antibody such as vedolizumab. Also provided herein is a kit containing the CCR9 inhibitor compound and anti-&#x3b1;4&#x3b2;7 integrin antibody.

Compositions and methods for treating inflammatory bowel disease using a combination therapy of small molecule inhibitors of C-C chemokine receptor type 9 (CCR9) and anti-&#x3b1;4&#x3b2;7 integrin blocking antibodies

Compositions and methods for treating inflammatory bowel disease using a combination therapy of small molecule inhibitors of C&#x2014;C chemokine receptor type 9 (CCR9) and anti-&#x3b1;4&#x3b2;7 integrin blocking antibodies

Provided herein are compositions, methods and kits for treating inflammatory bowel disease (IBD) such as Crohn's disease and ulcerative colitis in a mammal in need thereof. The method include administering to a subject with IBD a combination therapy containing a therapeutically effective amount of a chemokine receptor 9 (CCR9) inhibitor compound and a therapeutically effective amount of an anti-TNF&#x3b1; antibody. Also provided herein is a kit containing the CCR9 inhibitor compound and anti-TNF&#x3b1; antibody.

Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-TNF-alpha blocking antibodies

Compounds are provided that act as potent antagonists of chemokine receptors. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of chemokine receptor-mediated diseases, and as controls in assays for the identification of chemokine antagonists.

Bis-aryl sulfonamides

The inventors have discovered that a CK&#x3b2;8-1 truncation variant, CK&#x3b2;8-1 (25-116), is a bifunctional ligand for two distinct GPCRs, chemokine receptor CCR1 and formyl peptide receptor like 1 (FPRL1). Hence, the inventors have discovered that, in addition to its functional activity on CCR1, CK&#x3b2;8-1(25-116) is also a functional ligand for the GPCR receptor FPRL1 that is involved in inflammatory reactions and innate immunity by recruiting monocytes and neutrophils. In addition, the inventors have discovered an alternatively spliced exon of CK&#x3b2;8-1, named SHAAGtide. SHAAGtide, along with its parent chemokine CK&#x3b2;8-1 (25-116), is fully functional on both monocytes and neutrophils that are known to express FPRL1. This application relates generally to enhancing immune responses. Such immune responses may be elicited by vaccine administration. Compositions and methods for inducing or enhancing an immune response to an antigen are provided. The compositions and methods are useful for vaccine formulations for therapeutic and prophylactic use (immunization) and for production of antibodies.

Compositions useful as ligands for the formyl peptide receptor like 1 receptor and methods of use thereof

Growing community of inventors

Menlo Park, CA, United States of America

Thomas J Schall